Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ≥50% (vol 14, pg 1, 2022)

被引：0
|
作者：
Freemantle, N.
Xu, Y.
Wilson, F. R.
机构：
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2022年 / 14卷
关键词：
D O I：
10.1177/17588359221127078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
    Gumus, Mahmut
    Chen, Chieh-, I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri J. S.
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    CANCER, 2023, 129 (01) : 118 - 129
  • [32] Identifying Optimal First-Line Interventions for Advanced Non-Small Cell Lung Carcinoma According to PD-L1 Expression: A Systematic Review and Network Meta-Analysis
    Liu, J.
    Yu, J.
    Meng, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E131 - E132
  • [33] "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study"(vol 129, pg 118, 2023)
    Gumus, M.
    Chen, C-, I
    Ivanescu, C.
    CANCER, 2024, 130 (09) : 1715 - 1715
  • [34] Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis
    Liu, Jie
    Li, Chengming
    Seery, Samuel
    Yu, Jinming
    Meng, Xue
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [35] The role of PD-L1 expression as a predictive biomarker in advanced non-small cell lung cancer: A network meta-analysis
    Aguiar, P., Jr.
    Santoro, I.
    Tadokoro, H.
    Lopes, G.
    Filardi, B. A.
    Noia Barreto, C. M.
    Muniz, P. C.
    Picon, F. S.
    Borges, A. M.
    Oliveira, P.
    Mountzios, G.
    Riera, R.
    De Mello, R. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S644 - S644
  • [36] The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
    Banna, G. L.
    Cortellini, A.
    Cortinovis, D. L.
    Tiseo, M.
    Aerts, J. G. J., V
    Barbieri, F.
    Giusti, R.
    Bria, E.
    Grossi, F.
    Pizzutilo, P.
    Berardi, R.
    Morabito, A.
    Genova, C.
    Mazzoni, F.
    Di Noia, V
    Signorelli, D.
    Gelibter, A.
    Macerelli, M.
    Rastelli, F.
    Chiari, R.
    Rocco, D.
    Gori, S.
    De Tursi, M.
    Di Marino, P.
    Mansueto, G.
    Zoratto, F.
    Filetti, M.
    Montrone, M.
    Citarella, F.
    Marco, R.
    Cantini, L.
    Nigro, O.
    D'Argento, E.
    Buti, S.
    Minuti, G.
    Landi, L.
    Guaitoli, G.
    Lo Russo, G.
    De Toma, A.
    Donisi, C.
    Friedlaender, A.
    De Giglio, A.
    Metro, G.
    Porzio, G.
    Ficorella, C.
    Addeo, A.
    ESMO OPEN, 2021, 6 (02)
  • [37] Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    La-Beck, Ninh M.
    Nguyen, Dung T.
    Le, Alex D.
    Alzghari, Saeed K.
    Trinh, Saralinh T.
    PHARMACOTHERAPY, 2020, 40 (03): : 239 - 255
  • [38] First-Line Treatment Options for PD-L1-Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
    Peng, Ling
    Liang, Wen-Hua
    Mu, De-Guang
    Xu, Song
    Hong, Shao-Dong
    Stebbing, Justin
    Liang, Fei
    Xia, Yang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [39] The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis
    Yang, Yilin
    Pang, Peilin
    Xie, Zihong
    Wang, Nian
    Liang, Hengrui
    Zhao, Lei
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (05) : 3231 - +
  • [40] Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression
    Tambo, Yuichi
    Sone, Takashi
    Shibata, Kazuhiko
    Nishi, Kouichi
    Shirasaki, Hiroki
    Yoneda, Taro
    Araya, Tomoyuki
    Kase, Kazumasa
    Nishikawa, Shingo
    Kimura, Hideharu
    Kasahara, Kazuo
    CLINICAL LUNG CANCER, 2020, 21 (05) : E366 - E379
12345